BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • August 2023
  • July 2023
  • May 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2017
  • March 2014
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Subscribe
    • Uncategorized

Alterome Therapeutics Strengthens Leadership Team with Appointment of Renowned Oncologist Dr. Andrew S. Chi as Chief Medical Officer

    August 23, 2023 Alterome Therapeutics, Inc., a frontrunner in precision oncology, has…
    BioTech Health X
    • August 23, 2023
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

    BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

    • Jak Thomson
    • July 14, 2023

    Uncategorized11/19/21

    • BioTech Health X
    • May 30, 2023
    Welcome To BioTech Health X

    Biotech NewsWelcome To BioTech Health X

    • BioTech Health X
    • May 26, 2023
    Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data

    Biotech NewsRecent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data

    • BioTech Health X
    • May 9, 2023

    Most Trending
    Stories

    UncategorizedAlterome Therapeutics Strengthens Leadership Team with Appointment of Renowned Oncologist Dr. Andrew S. Chi as Chief Medical Officer

    • BioTech Health X
    • August 23, 2023
    Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

    BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

    • Jak Thomson
    • July 14, 2023

    Uncategorized11/19/21

    • BioTech Health X
    • May 30, 2023
    Welcome To BioTech Health X

    Biotech NewsWelcome To BioTech Health X

    • BioTech Health X
    • May 26, 2023
    Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data

    Biotech NewsRecent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data

    • BioTech Health X
    • May 9, 2023

    UncategorizedAlterome Therapeutics Strengthens Leadership Team with Appointment of Renowned Oncologist Dr. Andrew S. Chi as Chief Medical Officer

    • BioTech Health X
    • August 23, 2023
    August 23, 2023 Alterome Therapeutics, Inc., a frontrunner in precision oncology, has announced the addition of Dr. Andrew…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

    BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

    • Jak Thomson
    • July 14, 2023
    About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0

    Uncategorized11/19/21

    • BioTech Health X
    • May 30, 2023
    BioTech Health X Ortho Clinical Diagnostics Overview & Q&A Michael S. Iskra, Executive Vice President of Commercial Excellence…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    Welcome To BioTech Health X

    Biotech NewsWelcome To BioTech Health X

    • BioTech Health X
    • May 26, 2023
    The New Leader in BioTech News, BioTech Stock Information & BioTech Industry Analysis BioTech Health X delivers the…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data

    Biotech NewsRecent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data

    • BioTech Health X
    • May 9, 2023
    A recent report published by the American Association for Cancer Research titled Subgroup Analyses in Oncology Trials: Regulatory…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    Virios-Therapeutics-Stock-Plunges-70-on-Fibromyalgia-Clinical-Trial-Failure-Results

    Biotech NewsVirios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results

    • BioTech Health X
    • September 19, 2022
    In a shocking failure, Virios Therapeutics announced this morning pre-market that topline results from its FORTRESS (Fibromyalgia Outcome…
    Read More
    1 Shares
    1
    0
    0
    0
    0
    0
    0
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

    Biotech NewsCEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

    • BioTech Health X
    • September 10, 2022
    CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…
    Read More
    21 Shares
    21
    0
    0
    0
    0
    0
    0
    Mayo-Clinic-Gene-Accelerator

    Biotech NewsMayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator

    • BioTech Health X
    • August 31, 2022
    Mayo Clinic, Hibiscus BioVentures (Hibiscus), and Innoforce have announced the formation of Mayflower BioVentures, a cell and gene…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial

    Biotech NewsKrystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial

    • BioTech Health X
    • August 1, 2022
    Leader in redosable gene therapy Krystal Biotech, Inc. (NASDAQ: KRYS) announced today the United States Food and Drug…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug

    Biotech NewsImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug

    • BioTech Health X
    • July 28, 2022
    In breaking news, clinical-stage biotechnology company ImmunityBio, Inc. (NASDAQ: IBRX) has announced acceptance by the FDA review of…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement

    Biotech NewsBrickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement

    • BioTech Health X
    • July 20, 2022
    Clinical-stage pharmaceutical company Brickell Biotech, Inc. (Nasdaq: BBI) announced that the company has received formal notice from The…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

    Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

    • BioTech Health X
    • July 20, 2022
    Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0

    Biotech InfoWhat is Biotechnology: Types, Examples and Applications

    • BioTech Health X
    • June 24, 2022
    Understanding biotechnology Biotech involves studying organism functions at the molecular level and is often combined with many different…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    Ocugen Announces FDA Clinical Hold Removal for Phase 2:3 COVAXIN BBV152 Clinical Trial

    Biotech NewsOcugen Announces FDA Clinical Hold Removal for Phase 2/3 COVAXIN (BBV152) Clinical Trial

    • BioTech Health X
    • May 23, 2022
    Biotechnology company Ocugen, Inc. (NASDAQ: OCGN) announced today that the U.S. Food and Drug Administration (FDA) has removed…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    BenchSci Expands Advisory Board with New Pharma R&D Leaders

    Biotech NewsBenchSci Expands Advisory Board with New Pharma R&D Leaders

    • Jak Thomson
    • April 21, 2022
    BenchSci has welcomed three new members to its advisory board from the pharmacology sector. Steve Hitchcock of Takeda…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    EF Hutton Initiates Coverage of Cel-Sci CVM with 17 Price Target Ahead of Rumored News

    Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News

    • BioTech Health X
    • April 7, 2022
    Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    Legend Biotech Appoints Dr Guowei Fang Head of Global Research and Early Development

    Biotech NewsLegend Biotech Appoints Dr. Guowei Fang As Head of Global Research and Early Development

    • BioTech Health X
    • April 1, 2022
    Global biotechnology company Legend Biotech Corporation (NASDAQ: LEGN) announced today that Guowei Fang, Ph.D. will take over as…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    2seventy-bio-Secure-170-Million-Extending-Cash-Runway-Into-2025

    Biotech News2seventy bio Secure $170 Million Extending Cash Runway Into 2025

    • BioTech Health X
    • March 16, 2022
    2seventy bio (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that it has agreed to sell…
    Read More
    0 Shares
    0
    0
    0
    0
    0
    0
    0
    Recent Posts
    • Alterome Therapeutics Strengthens Leadership Team with Appointment of Renowned Oncologist Dr. Andrew S. Chi as Chief Medical Officer
    • Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
    • 11/19/21
    • Welcome To BioTech Health X
    • Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
    Recent Comments
    • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
    • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
    • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
    Featured Posts
      • August 23, 2023
      Alterome Therapeutics Strengthens Leadership Team with Appointment of Renowned Oncologist Dr. Andrew S. Chi as Chief Medical Officer
      • July 14, 2023
      Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
      Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
      • May 30, 2023
      11/19/21
      • May 26, 2023
      Welcome To BioTech Health X
      Welcome To BioTech Health X
      • May 9, 2023
      Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
      Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
    Recent Posts
    • Inhibikase-Therapeutics-Present-Phase-1-1b-Trial-Results-ADPD-Alzheimers-Parkinsons-Diseases-Conference
      Inhibikase Therapeutics To Present Phase 1/1b Trial Results at AD/PD Alzheimer’s & Parkinson’s Diseases Conference
      • March 8, 2022
    • Celyad-Oncology-Pauses-CYAD-101-002-Keynote-B79-Phase-1-Trial-After-2-Deaths-Reported
      Celyad Oncology Pauses CYAD-101-002 (Keynote-B79) Phase 1 Trial After 2 Deaths Reported
      • February 28, 2022
    • Cellarity-Expands-Leadership-Team-to-Continue-Evolution-of-Breakthrough-Platform-to-Encode-Biology-and-Purposefully-Create-New-DrugsCellarity-Expands-Leadership-Team
      Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
      • February 10, 2022
    Categories
    • BioTech CEO Interviews (4)
    • Biotech Info (1)
    • Biotech News (44)
    • Uncategorized (2)
    Author
    Hello, I’m
    BioTech Health X
    Follow
    BioTech Health X
    Designed & Developed by BioTech Health X
    • Our Contributors
    • List of Modern Life Science Technologies
    • Contact Us

    Subscribe to
    Our Updates

    Back to top